5 Questions Facing Biopharma in 2026

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline…

5 questions facing biopharma in 2026

The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026 10:30 ET  | Source: BridgeBio Pharma, Inc. – Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively – Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, […] The post BridgeBio Announces Commercial Progress, Program Updates,…

5 questions facing biopharma in 2026 – RamaOnHealthcare

The biopharmaceutical sector finally regained its footing in 2025. Here are 5 issues that could determine whether the renewed optimism will carry over into the new year.Even in the darkest of times, biopharmaceutical investors and executives usually express optimism in January, when thousands gather in San Francisco for the annual J.P. Morgan Healthcare Conference to [...]